Акромегалия: особенности клинической картины, осложнений, эффективность различных методов лечения
Диссертация
Оценить эффективность медикаментозного лечения акромегалии длительно действующими аналогами соматостатина (соматулином, сандостатином ЛАР, октреотидом-депо) в качестве предоперационной подготовки, дополнительной и первичной терапии на основании динамики клинических, гормональных признаков активности заболевания, размеров опухоли гипофиза, степени экспрессии маркеров опухолевой прогрессии… Читать ещё >
Список литературы
- Балаболкин М.И., Клебанова Е. М., Кремннская В. М. Дифференциальная диагностика и лечение эндокринных заболеваний: Руководство, — М.: Медицина, 2002, — 752 с.
- Баранов B.JI. Патогенез, диагностика и лечение нарушений сердечнососудистой системы у больных симптоматическими артериальными гипертензиями эндокринного генеза: Автореф. дис. .докт. мед. наук. -СПб., 1997.
- Баум О.В., Попов Л. А., Волошин В. И., Муромцева Г.А. QT-дисперсия в ортогональных и псевдоортогональных системах отведений. // Вестник аритмологии. 2002. — № 26. — С. 49−56.
- Баум О.В., Попов Л. А., Волошин В. И., Муромцева Г.А. QT-дисперсия: модели и измерения. // Вестник аритмологии. 2000. — № 20. — С. 6−17.
- Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению '// Русский медицинский журнал. -2001.- Т. 9,-№ 2-С. 56−60.
- Дедов И.И., Молитвословова H.H., Марова Е. И. Акромегалия: патогенез, клиника, диагностика, дифференциальная диагностика, методы лечения. Пособие для врачей Тверь: ООО «Издательства «Триада», 2003.- С. 40.
- Дедов И.И., Фадеев В. В. Введение в диабетологию (Руководство для врачей). М.: Издательство Берег, 1998. — С. 200.
- Кадин Д.В. Состояние миокарда у больных некоторыми симптоматическими гипертензиями до и в различные сроки после хирургического лечения.: Дис.. канд. мед. наук. СПб., 1998.
- Кобалава Ж.Д., Котовская Ю. В. Артериальная гипертония в вопросах и ответах: Справочник практикующих врачей. Под ред. чл.-корр. РАМН B.C. Моисеева. М.: «Форте Арт.», 2002. — 100с.
- Кобалава Ж.Д., Терещенко С. Н., Калинкин А. Л. Суточное мониторирование артериального давления: методические аспекты иклиническое значение. Под редакцией проф. Моисеева B.C. Москва, 1997. -С. 32.
- Кяндарян Г. Г. Состояние сердечно-сосудистой системы при акромегалии.: Дис.. канд. мед. наук. М., 1979.
- Марова Е.И. //Нейроэндокринология: клинические очерки / Под редакцией Е. И. Маровой. Ярославль, 1999.- С. 506.
- Марова Е.И., Авакян М. Р., Подлящук E.J1. и др. Результаты дистанционной гамма-терапии у больных акромегалией // Проблемы эндокринологии 1991. — Т. 37. -№ 1.- С. 22−25.
- Молитвословова Н.Н. Роль соматотропина и гормонов поджелудочной железы в генезе нарушений углеводного обмена при акромегалии.: Дис.. канд. мед. наук. М., 1983.
- Никитин Ю.П., Кузнецов А. А. Дисперсия интервала QT. // Кардиология. -1998. -№ 5.-С. 58−63.
- Рогоза А.Н. Суточное мониторирование артериального давления. // Сердце. 2002. — Т. 1. — № 5. — С. 240 — 242.
- Шиллер Н., Осипов М. А. Клиническая эхокардиография. М., 1993. С. 347.
- Шустов С.Б. Кардиологические и эндокринные аспекты симптоматических артериальных гипертензий.: Дис.. докт. мед. наук. -СПб., 1993.
- Abbasi F., Brown B.W.Jr., Lamendola С. et al. Relationship between obesity, insulin resistance, and coronary heart disease risk // J. Am. Coll. Cardiol. 2002. — Vol. 40, № 5. — P. 937−943.
- Abe Т., Ludecke D.K./ Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre// Eur.J. Endocrinol. 2001, 145, pp. 137−145.
- Abs R, Verhelst J, Matter D, et al/ Cabergoline In the treatment of acromegaly: A study in 64 patients// J Clin Endocrinol Metab 1998. -83(2):374−78.
- ACC/AHA Guidelines for Ambulatory Electrocardiography. JACC. 1999. -Vol. 34, № 3,-P. 912−948.
- Acromegaly a handbook of history, current therapy and future prospects. Edited by J AH Wass/Bio Scientifica, Bristol, UK, 2009. P. 214.
- Acromegaly pathology, diagnosis and treatment/ Taylor and Francis group, LLC. USA, 2005, p. 151.
- Alexopoulou O., Bex M., Abs R./Divergence between growth hormone and insulin-like groth factor-1 concetrations in the follow up of acromegaly//!. Clin/Endocrinol Metab 2008. — V93. — № 4/ P.1324−1330.
- Amato G., Mazziotti G., Rotondi M. et al/ Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.// Clin. Endocrinol (Oxf) 2002. — N56, pp. 6571.
- Aoyagi S., Fukunaga S., Teshima H. et al. Mitral valve repair in a patient with acromegaly: case report. // Cire. J. 2002. — Vol. 66, № 5. P. 522−524.
- Arita K., Tominaga A./Short and long term effects of transspenoidal surgery on growth hormone producing pituitary adenomas: based on experiences with 290 patients.//14th ICE 2010. Endocrinologica Japonica, V57, suppl. 2, S280, SY 104−2.
- Arosio M., Macchelli S., Rossi C.M., et al/ Effects of treatment with octreotide in acromegalic patients a multicenter Italian study//Eur. J. Endocrinol., 1995,133, pp.430−439.
- Arosio M., Sartore G., Rossi C. et al. LDL physical properties, lipoprotein and Lp (a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group // Atherosclerosis. 2000. — Vol. 151, № 2. -P. 551−557.
- Attanasio R., Barausse M., Cozzi R.,/GH/IGF-1 normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide/ J. Endocrinol. Invest. 2001. — N24, pp. 209−216.
- Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with
- Acromegaly. J Clin Endocrinol Metab 2004. — 89(4): 1613−1617.
- Ayuk J., Stewart S., Stewart P., Sheppard M/ Long-term safety and efficacy of deport long-acting somatostatin analogs for the treatment of acromegaly/ Journal of Clinical Endocrinology and Metabolism 2002. — V87, N 9, pp. 4142−4146.
- Badia X, Webb SM, Prieto L, Lara N. Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes 2004- 2(1): 13.
- Baldvinsdottir T., Jonasson J.G., Thorsson A.V. et al/Epidemiology of pituitary tumorous in Iceland 1955−2007: a Nationwide study// 10th European Congress of Endocrinology, 3−7 May, Berlin, Germany. Endocrine Abstracts, May 2008, VI6, P315.
- Baldwin A., Cundy T., Butler J. et al. Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation. // Acta Endocrinol. (Copenh). -1985. Vol. 108, № 3 1. — p. p. 26−30.
- Baldys-Waligorska A, Krzentowska A, Golkowski F, Sokolowski G, Hubalewska-Dydejczyk A./The prevalence of benign and malignant neoplasms in acromegalic patients.// Pol J Endocrinol 2010. — 61 (1): 29−34
- Bardelli R., Colao A., Razzore P. et al/ Two-year follow-up of acromegaly patients treated with slow release lanreotide (30 mg)// Journal of Clinical Endocrinology and Metabolism 2000.- 85,4099−4103.
- Barkan A. Radiotherapy in acromegaly: the argument against // Clinical Endocrinology. 2003. — V 58, pp. 132−135.
- Barkan A., Halasz I, Dornfeld KJ, et al. Pituitary radiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 1997. — 82, pp. 3187−3191.
- Barkan A./ Currrent management of acromegaly// 14th ICE 2010. Endocrinologica Japonica, V57, suppl. 2, S280, SY 10−4-1.
- Barros L., Paiva I., Rodrigues D. et al. The prevalence of hypertension in acromegaly. // Acta Med. Port. 1997. — Vol. 10, № 1. — P. 15−18.
- Bates AS, Van’t Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993. — 86(5):293−299.
- Bates AS, Van’t Hoff W, Jones JM, et al. Does treatment of acromegaly affect life expectancy? Metabolism 1995- 44 (suppl. 1)1−5.
- Bengtsson B, Eden. S., Ernest, I, Oden A. & Sjogren B. Epidemiology and long term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Medica Scandinavian 1988. — 223(4), p. 327 335.
- Bevan John /Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly//The J. of Clinical Endocr. Metab. 2005. — V90, N3, pp. 1856−1863.
- Bezante G., Pestelli S., Gnecco G. et al. Morphologic and functional evaluation of the left ventricle in patients with acromegaly. An echocardiographic study// Minerva Cardioangiol. 1990. — Vol. 38, № 1−2. — P. 11−16.
- Biermasz N.R., van Dulken, H. & Roelfsema, F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2000. — 85, pp. 2476−2482.
- Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F./Morbidity after long-term remission for acromegaly- persisting joint-related com plaints cause reduced quality of life.//J. Clin. Endocrinol. Metab. 2005 -90(5):2731−2739.
- Biermasz NR, van Dulken H., Roelfstma F./Ten-year follow-up results of transsphenoidal microsurgery in acromegaly// J. Clin. Endocrinol. Metab. -2000, — 85 (12):4596−4602.
- Bondanelli M., Ambrosio M., Franceschetti P. et al./Diurnal rhythm of plasma catecholamines in acromegaly. // J. Clin. Endocrinol. Metab. 1999. — Vol. 84, № 7. — P. 2458−2467.
- Bonert V.S., Carmichael J.D., Barnett P., Melmed S./10 year treatment outcome in 100 patients with acromegaly//90th Annual Meeting, San Francisco, 2008. Abstracts book, P2−738.
- Bourdelot A., Coste J., Hazebroucq V. et al/ Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome.//European journal of endocrinology -2004.-V. 150.- № 6.-P.763−771.
- Brada M., Ashley S., Ford D. et al/Cerebrovascular mortality in patients with pituitary adenoma// Clinical Endocrinology, 2002, N 57, pp. 713−717.
- Brazeau P, Vale W, Burgus R, Ling M, Rivier Y, Guillemin R. Hypothalamic peptide that inhibits the secretion of immunoreactive growth hormone, Science, 1973, 179, pp.77- 79.
- Bruch C., Herrmann B., Schmermund A. et al. /Impact of disease activity on left ventricular performance in patients with acromegaly. // Am. Heart J. 2002. -Vol. 144, № 3.-P. 538−543.
- Burt M.G. and K.K.Y. Ho/Newer options in the management of acromegaly/ // Internal Medicine Journal, 2006, N36, pp. 437−444.
- Caron P. /Lanreotide autogel in acromegaly and neuroendocrine tumors//Therapy, 2007, V4, N1, pp. 9−29.
- Caron P., Morange-Ramos I., Cogne M. & Jaquet P/Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide/ //J. Clin. Endocrinol. Metab., 1997, V82, N1, pp. 18−22.
- Cavalli G., De Gregorio C., Nicosia S. et al. Acromegalic cardiopathy: a morphofunctional study with color-Doppler echocardiography. // Ann. Ital. Med. Int. 1992 — Vol. 7, № 3. — pp. 141−147.
- Chanson P., Boerlin V., Ajzenberg C. et al/ Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly//Clinical Endocrinology, 2000, V. 53, N 5, pp. 557−586.
- Ciulla M., Arosio M., Barelli M. et al. Blood pressure-independent cardiac hypertrophy in acromegalic patients. // J. Hypertens. 1999. — Vol. 17, № (12 Pt 2).-pp. 1965−1969.
- Clayton R.N. Cardiovascular function in acromegaly. // Endocr. Rev. 2003. -Vol. 24, № 3. pp. 272−277.
- Colao A, Spinelli L, Marzullo P, et al/High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab. 2003. 88:3196−3201.
- Colao A., A. Cuocolo, P. Marzullo et al/Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly// The J. of Clinical Endocr. Metab., 1999, V84, N1, pp. 17−23
- Colao A., Baldelli R., Marzullo P. et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. // J. Clin. Endocrinol. Metab. 2000a. — Vol. 85, № 1. — pp. 193−199.
- Colao A., Ferone D., Marzullo P. et al/Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly// The J. of Clinical Endocrinol. Metab. 2001, V 86, N6, pp. 27 792 786.
- Colao A., Marzullo P., Di Somma C., Lombardi G. Growth hormone and the heart. // Clin. Endocrinol. (Oxf). 2001a. — Vol. 54, № 2. — P. 137−154.
- Colao A., Marzullo P., Ferone D. et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. // J. Clin. Endocrinol. Metab. 2000b. — Vol. 85, № 9. — P. 3132−3140.
- Colao A., R. Attanasio, R. Pivonello et al/ Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatinanalogs in acromegaly// The J. Clin. Endocrinol. Metab. 2006, V 91, N1, pp.85−92.
- Colao A., Spiezia S., Cerbone G. et al. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly // Clin. Endocrinol. (Oxf). 2001, Vol. 54, № 4. P. 515−524.
- Cozzi R., Attanasio R., Montini M. et al/Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results// The J. Clinic. Endocrinol. Metab. 2003. — V88, N7, pp. 30 903 098.
- Cozzi R., Barausse M., Sberna M. et al// Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly/ Pituitary. 2000. — N3. — pp. 231−238.
- Cozzi R., Dallabonzana D., Attanasio R. et al /A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly/ // European Journal of Endocrinology// 1999. N 141, pp. 267−271.
- Cozzi R., Lasio G., Felisati G. et al/Transsphenoidal adenomectomy by endoscopic technique in acromegaly: a single center experience////90th Annual Meeting, San Francisco, 2008. Abstracts book, P2−741.
- Cuocolo A., Nicolai E., Fazio S. et al. Impaired left ventricular diastolic filling in patients with acromegaly: assessment with radionuclide angiography. // J. Nucl. Med. 1995, Vol. 36, N 2, pp. 196−201.
- Davies P.H., Stewart S.E., Lancranjan I. et al/Long-term therapy with long acting octreotide (Sandostatin-LAR) for the management of acromegaly//Clinical Endocrinology. 1998. — 48, pp. 311−316.
- Dekkers O.M., Biermasz N.R., Pereira A.M. et al/ Mortality in acromegaly: a metaanalysis// J. Clinic. Endocr. Metab. 2008.- V 93. — № 1- P. 61−67.
- DeLisser HM, Newman PJ, Albelda SM/Molecular and functional aspects of PECAM-l/CD31//Immunol Today.-1994, 15:490−495.
- Devereux R.B., Lutus E.M., Casule P.N. et al. Standartization of M-mode echocardiographic left ventricular anatomic measurements. // J. Am. Coll. Cardiol, 1984, N4, pp. 1222 1230.
- Diamanti E., Malachtari S., Thomas F., Tolis G./Efficacy of slow release formulation of the new somatostatin analogue lanreotide in acromegaly// The Endocrine Society, Las Vegas, 1993, Abstract 72, 68.
- Dominik Riss, Long Jin, Xiang Qian/Differential expression of galectin -3 in pituitary tumors//Cancer Research- 2003. May 1.-63. P.2251−2255.
- Elias P.C.L, Lugao H.B., Pereira M.C. et al/Acromegaly activity after treatment evalution of patients with discordant nadir GH on OGTT and IGF-I levels//90th Annual Meeting, San Francisco, 2008. Abstracts book, P2−730.
- Ezzat S., Forster M., Berchtold P. et al. Clinical and biochemical features in 500 patients. // Medicine (Baltimore), 1994, Vol. 73, N 5, pp. 233−240.
- Ezzat S., Horvath E., Harris A.G. et al/ Morphological effects of octreotide on growth hormone-producing pituitary adenomas // J. Clin. Endocrinol. Metab., 1994, V79, N1, pp.113−118.
- Ezzat S., Snyder P.J., Young W.F. et al Octreotide treatment of acromegaly./ A randomized, multicenter study // Ann. Intern. Med., 1992, VI17, pp.711−718.
- Fahlbusch R., Buchfelder M., Kreutzer J. et al/ Surgical management of acromegaly// Handbook of acromegaly/ed.J.Wass. Published by Bioscientifica, Bristol, UK, 2001, pp. 41−47.
- Fazio S., Cittadini A., Cuocolo A. et al. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. // J. Clin. Endocrinol. Metab. -1994. Vol. 79, N 2. — pp. 441−446.
- Fazio S., Cittadini A., Sabatini D. et al. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study. // Eur. Heart J. 1993, Vol. 14, N 1. — pp. 26−33.
- Fazio S., Cittadini A., Sabatini D. et al. Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. // Eur. Heart J. 1997. — Vol. 18, № 2. — pp. 340−347.
- Fazio, S., Cittadini, A., Biondi, B. et al /Cardiovascular effects of short-term growth hormone hypersecretion.// Journal of Clinical Endocrinology and Metabolism 2000. — 85, N1, pp. 179−182.
- Fernandez A., Karavitaki N. & Wass JAH/High prevalence of pituitary adenomas: a cross-sectional study in the city of Banbury (Oxfordshire)// 10th European Congress of Endocrinology, 3−7 May, Berlin, Germany. Endocrine Abstracts, May 2008, V16, P337.
- Flogstad A.K., J. Halse, S. Bakke et al/Sandostatin LAR in acromegalic patients: long term treatment//The J. of Clinical Endocrinol. Metab. 1997. — V 82, N l, pp. 23−28.
- Freda Pamela U., Katznelson Laurence, Aart Jan van der Lely et al/ Long-acting somatostatin analog therapy of acromegaly: a meta-analysis// The J. of Clin. Endocr. Metab. 2005. — V90, N8, pp. 4465−4473.
- Freda PU and Wardlaw Sh L/ Editorial: Primary medical therapy for acromegaly// J Clin Endocrinol Metab, 1998, V 83, N 9, pp. 3031−3033.
- Frustaci A., Chimenti C., Setoguchi M. et al. Cell death in acromegalic cardiomyopathy. // Circulation, 1999, Vol. 99, N 11, pp. 1426−1434.
- Fukuda I., Hizuka N Murakami Y. et al/Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women’s Medical University // Intern. Med. 2001. Vol. 40, № 10. — P. 987−992.
- Fukuda I., Hizuka N., Kurimoto M. et al/The influences of thethstandartization of GH assay on the remission criteria for acromegaly//90 Annual Meeting, San Francisco, 2008. Abstracts book, P2−717.
- Fukui S., Nawashiro H. Otani m et al/Vascular endothelial growth factor expression in pituitary adenomas//Acta Neurohir.Suppl. -2003.86:519−521.
- Fukuoka H., Takahashi Y., Kudo T. et al/Hypertriglyceridemia is associated with serum GH levels in active acromegaly with abnormal glucose tolerance// 90th Annual Meeting, San Francisco, 2008. Abstracts book, P2−722.
- Galanti G., Cappelli B., Diricatti G. et al. Systolic and diastolic cardiac function in acromegaly. An echocardiographic study. // Ann. Ital. Med. Int., 1996, Vol. 11, N 1, pp. 27−32.
- Gasperi M., Martino E., Manetti L. et al/Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study//J. Clinical Invest. 2002. — V25, N3, pp. 240−245.
- Giusti M., Bocca L., Ferrari E. et al/ Long-term effects of somatulin on GH and IGF-I hypersecretion in acromegaly: single-centre study/.//6-th European congress of Endocrinology, Lyon, April 2003. — P1059.
- Giustina A., Barkan A., Casanueva F.F. et al Criteria for cure of acromensgaly: a consensus statement. // The Journal of Clinic. Endocr. Metab. 2000 V. 85, N 2. pp. 526−529.
- Gullu BE, Celik O, Gazioglu N, Kadioglu P./Thyroid cancer is the most common cancer associated with acromegaly.// Pituitary.- 2010. Sep- 13(3):242−248.
- Gyongyosi M., Valkusz Z., Varga A. et al. 15-year echocardiographic follow-up of acromegalic patients. // Orv. Hetil. 1995. — Vol. 136, № 29. — P. 15 391 544.
- Hall J., Hildebrandt D., Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. // Am. J. Hypertens. 2001. — 14(6 Pt 2): S. 103 115.
- Hall R, Besser GM, Schally A, ct al. Actions of growth hormone release inhibitory hormone in healthy men and in acromegaly. Lancet, 1973, 2, pp. 581 584.
- Harris A. Acromegaly and its management. Philadelphia. USA: Lippincott Raven Publishers — 1996. — P. 175.
- Hashimoto K., Yamanaka M., Uchida H. et al. A patient with acromegalic heart disease-a case report. // Masui. 1997. — Vol. 46, № 7. — P. 951−954.
- Helen E. Turner. Clinical features, investigation and complications of acromegaly/ Handbook of acromegaly// ed. J.Wass. Bioscientifica, UK, 2001, pp. 19−28.
- Hennessey J. V. Jackson I.M.D. Clinical feathres of pituitary tumorous // Clin. Endocr. and Metab., Pituitary tumours, ed. J.A. Fagin. 1995. — № 9. — P. 288 314.
- Heron I., Thomas F., Dero M. et al /Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analogue BIM 23 014 in the patients with acromegaly //The Journal of Clinical Endocrinol. Metab. 1993. — V. 73, pp. 721−723.
- Herrmann B., Bruch C., Sailer B. et al. Occurrence of ventricular late potentials in patients with active acromegaly. // Clin. Endocrinol. (Oxf). 2001. — Vol. 55, № 2. — P. 201−207.
- Herrmann B.L., Bruch C., Sailer B. et al. Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy. // Clin. Endocrinol. (Oxf). 2002. — Vol. 56, № 5. — P. 595−602.
- Holdaway I.M., Rajasoorya C./ Epidemiology of acromegaly.// Pituitary -1999. 2(1):29−41
- Holdaway I.M., Rajasoorya R.C., Gamble G.D./ Factors influencing mortality in acromegaly.// J Clin Endocrinol Metab 2004. — 89(2):667−674.
- Hradec J., Marek J., Krai J. et al. Long-term echocardiographic follow-up of acromegalic heart disease. // Am. J. Cardiol. 1993. — Vol. 72, № 2. — P. 205 210.
- Hradec J., Marek J., Petrasek J. The nature of cardiac hypertrophy in acromegaly: an echocardiographic study. // Cor Vasa. 1988. — Vol. 30, № 3. -P. 186−199.
- Ip M.S.M., Tan K.C.B., Peh W.C.G., Lam K.S.L./Effect of sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity//Clinical Endocrinology 2001. — 55, pp. 477−483.
- Jackson D. E/The infolding tale of PEC AM-1 //FEB S Lett. 2003.- 540:7−14.
- Jaffrain-Rea M., Minniti G., Moroni C. et al. Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. // Eur. J. Endocrinol. 2003. — Vol. 148, № 2. — P. 193−201.
- Jaffrain-Rea M., Moroni C., Baldelli R. et al. Relationship between blood pressure and glucose tolerance in acromegaly// Clin. Endocrinol. (Oxf). -2001. Vol. 54, № 2, P. 189−195.
- Jane JA, Vance ML, Woodburn CJ, Laws ER Jr. Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach. Neurosurgis 2003. — N14, pp. 1−5.
- Jenkins P.J., Plowman Nicolas P./ Radiotherapy for acromegaly//Handbook of acromegaly//ed. J. Wass. Bristol, Bioscientifica, UK 2001, pp. 67−76.
- Jenkins P.J., Sohaib S.A., Akker S. et al/The pathology of median neuropathy in acromegaly//Ann Intern Med 2000. — VI33, N3, pp. 197−201.
- Jensen J.G./Self-observations of total life situation in patients with Acromegalia//10th European Congress of Endocrinology, 2008, 3−7 May, Berlin, Germany. Endocrine Abstracts, May, 2008, VI6, P319.
- John A Jane Jr and Edward R. Laws /History of acromegaly //Handbook of acromegaly ed. J. Wass// Bristol, Bioscientifica, UK, 2001, pp. 3−15.
- Kahaly G., Olshausen K., Mohr-Kahaly S. et al. Arrhythmia profile in acromegaly. // Eur. Heart J. 1992. — Vol. 13, № 1. — P. 51−56.
- Kasayama S., Otsuki M., Takagi M. et al. Impaired beta-cell function in the presence reduced insulin sensitivity determines glucose tolerance status in acromegalic patients // Clin. Endocrinol. (Oxf). 2000. — Vol. 52, № 5. — P. 549−555.
- Kim, M.S., Lee, S.I. & Sim, J.H./ Gamma-knife radiosurgery for functioning pituitary microadenoma.//Stereotactic and Functional Neurosurgery, 1999, 72, pp.119−124.
- Kokot F., Adamczak M., Wiecek A. Cieplok J. Does leptin play a role in the pathogenesis of essential hypertension? // Kidney Blood Press. Res. 1999. -Vol. 22, № 3.-P. 154−160.
- Kraatz C., Benker G., Weber F. et al. Acromegaly and hypertension: prevalence and relationship to the renin-angiotensin-aldosterone system. // Klin. Wochenschr. 1990. — Vol. 68, № 12. — P. 583−587.
- Kreutzer, J., Vance, M. L, Lopes, M.B.S., Laws, E.R./ Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.// Journal of Clinical Endocrinology and Metabolism 2001. — 86 (9): pp. 4072−4077.
- Kreze A., Kreze-Spirova E., Mikulecky M. Risk factors for glucose intolerance in active acromegaly // Braz. J. Med. Biol. Res. 2001. — Vol. 34, № 11. — P. 1429−1433.
- Lancranjan I., B. Atkinson A., & the Sandostatin LAR Group. Results of a European Multicentre study with sandostatin LAR in acromegaly patients// Pituitary 1999. — 1, pp. 105−114.
- Landin-Wilhelmsen K., Tengborn L., Wilhelmsen L, Bengtsson B. Elevated fibrinogen levels decrease following treatment of acromegaly // Clin. Endocrinol. (Oxf). -1997. Vol. 46, № 1. — P. 69−74.
- Lath R., Chacko G., Chandy M.J./ Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody//Neurol India. -2001.-Jun.-49(2): 144−147.
- Legrand V., Beckers A., Pham V. et al. Dramatic improvement of severe dilated cardiomyopathy in an acromegalic patient after treatment with octreotide and trans-sphenoidal surgery. // Eur. Heart J. 1994. — Vol. 15, № 9. — P. 12 861 289.
- Liuzzi A, Chiodini PG, Botalla L, Cremascoli G & Silvestrini F./ Inhibitory effect of 1-dopa on GH release in acromegalic patients// Journal of Clinical Endocrinology and Metabolism, 1972, 35, pp. 941−943.
- Lloyd RV, Scheithauer BW, Kuroki T. et al/Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas//Endocr. Pathol. -1999.-10:229−235.
- Lombardi G., Colao A., Marzullo P. et al. Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. // J. Endocrinol. 1997. — 155 Suppl l: S33−7- discussion S39.
- Lombardini G., Colao A., Ferone D. et al/ CV205−502 treatment in therapy-resistant acromegalic patients // European Journal of Endocrinology, 1995, V 132, pp. 559−564.
- Lopez-Velasco R., Escobar-Morreale H., Vega B. et al. Cardiac involvment in acromegaly: spesific myocardiopathy or consequence of systemic hypertension? // J. Clin. Endocrinol. Metab. 1997. — Vol. 82, № 4. — P. 10 471 053.
- Losa M., Ciccarelli E., Mortini P. et al/ Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas // J. Clin. Endocrinol. Metab., 2001, V86, pp. 5194−5200.
- Losa M. Picozzi P., Mortini P. /Surgery followed by gamma knife radiosurgery for treatment of acromegaly//14th ICE 2010. Endocrinologica Japonica, V57, suppl. 2, S280, SY 10−4-3.
- Lundin P., Engstrom B.E., Karisson F./A Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR//AJNR Am.J. Neuroradiol, 1997, N18, pp. 765−772.
- Maffei P., Corfini A., de Carlo E. et al. Gender-dependent variability of signal-averaged electrocardiogram in acromegaly. // Cardiology. 1995. — Vol. 86, № 2.-P. 114−119.
- Maison P., Demolis P., Young J. et al. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. // Clin. Endocrinol. (Oxf). 2000. — Vol. 53, № 4.445.451.
- Mallamaci F., Cuzzola F., Tripepi G. et al. Gender-dependent differences in plasma leptin in essential hypertension. // Am. J. Hypertens. 2000. — Vol. 13, № 8.-P. 914−920.
- Manelli F, Desenzani P, Bon E, et al/ Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy// Pituitary, 1999, V 2, N 3, pp, 205−210.
- Marek J/Radiotherapy in pituitary tumors//14th Congress of ENEA.- 2010. 22−25 September, Liege, Belgium. Abstract book. — MTP-10, p. 26.
- Marin F., Pico A., Martinez J. et al. Biventricular impairment of diastolic function in acromegaly. // Rev. Esp. Cardiol. 2001. — Vol. 54, № 1. — P. 37−42.
- Marin F., Pico A., Martinez J. et al. Heart disease in acromegaly. Study of 27 patients. // Med. Clin. (Bare). 1996. — Vol. 107, № 9. — P. 326−330.
- Mastronardi L., Guiducci A., Spera C. et al/Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody//J.Clin.Pathol. -1999- Feb. -52(2): 107−111.
- Matturri L., Varesi C., Nappo A. et al. Sudden cardiac death in acromegaly. Anatomopathological observation of a case. // Minerva Med. 1998. — Vol. 89, № 7−8.-P. 287−291.
- McCabe CJ, Khaira JS, Sheppard MC et al/Pituitary tumor transforming gene, basic fibroblast growth factor and vascular endotelial growth factor expression in sporadic pituitary adenomas.//Pituitary. 2000. — 3:22.
- Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. AACE. // Endocrine practice, 2004, V 10, N3, pp. 213−225.
- Melmed S., Casanueva F., Cavagnini F. et al/ Consensus statement: medical management of acromegaly //European Journal of Endocrinology, 2005, 153, pp. 737−740.
- Melmed S., Casanueva F. F, Cavagnini F. et al/Consensus. Guidelines for acromegly management // The Journal of Clinical Endocrinol. Metab, 2002, V 87, N 9, pp. 4054−4058.
- Mercuro G., Zoncu S., Colonna P. et al. Cardiac dysfunction in acromegaly: evidence by pulsed wave tissue Doppler imaging. // Eur. J. Endocrinol. 2000. -Vol. 143, № 3,-P. 363−369.
- Meyers D.E., Cuneo R.C. Controversies regarding the effects of growth hormone on the heart. // Mayo Clin. Proc. 2003. — Vol. 78, № 12. — P. 15 211 526.
- Minniti G., Jaffrain-Rea M., Moroni C. et al. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. // Clin. Endocrinol. (Oxf). 1998. — Vol. 49, № 1. — P. 101 106.
- Minniti G., Moroni C., Jaffrain-Rea M. et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. // Clin. Endocrinol. (Oxf). 2001. — Vol. 55, № 3. — P. 307−313.
- Mohamed A., Yusoff K., Muttalif A., Khalid B. Markers of ventricular tachyarrythmias in patients with acromegaly. // Med. J. Malaysia. 1999. — Vol. 54, № 3,-P. 338−345.
- Morvan D., Komajda M., Grimaldi A. et al. Cardiac hypertrophy and function in asymptomatic acromegaly. // Eur. Heart J. 1991. — Vol. 12, № 6. — P. 666 672.
- Mota F., Matos K., Afonso M. et al / Pituitary adenomas: the reality of Braga// 10th European Congress of Endocrinology, 3−7 May, Berlin, Germany. Endocrine Abstracts, May 2008, V16, P344.
- Mustacchi P, Shimkin MB./ Occurrence of cancer in acromegaly and in hypopituitarism.//Cancer 1997- 10: 100—104.
- Nabarro J.D. Acromegaly. Clin Endocrinol (Oxf), 1987, 26, 4, 481−512.
- Newman C.B., Melmed S., George A. et al/ Octreotide as primary therapy for acromegaly// The J. of Clinical Endocrinol. Metab., 1998, V83, N9, pp. 30 343 040.
- Newman PJ, Newman DK/Signal transduction pathways mediated by PECAM-1. New roles for an old molecule in platelet and vascular cell biology/ Arterioscler Thromb Vase Biol 2003.-23:953−964.
- Ohtsuka G., Aomi S., Koyanagi H. et al. Heart valve operation in acromegaly. // Ann. Thorac. Surg. 1997. — Vol. 64, № 2. — P, 390−393.
- Ohtsuka H., Komiya I., Aizawa T., Yamada T. Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-I production. // Endocr. J. 1995. — Vol. 42, № 6. — P. 781−787.
- Orme SM, McNally RJ, Cartwright RA, Belchetz PE./Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group// J Clin Endocrinol Metab. 1998. — 83, (8):2730−2734.
- Otsuki M., Kasayama S., Yamamoto H. et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients // Clin. Endocrinol. (Oxf). 2001. — Vol.54, № 6 — P. 791 -796.
- Ozbey N., Oncul A., Bugra Z. et al. Acromegalic cardiomyopathy: evaluation of the left ventricular diastolic function in the subclinical stage. // Endocrinol. Invest. 1997. — Vol. 20, № 6. -P. 305−311.
- Paolisso G., Tagliamonte M., Galderisi M. et al. Plasma leptin concentration, insulin sensitivity, and 24-hour ambulatory blood pressure and left ventricular geometry. // Am. J. Hypertens. 2001. — Vol. 14, № 2. — P. 114−120.
- Paolisso G., Tagliamonte M., Galderisi M. et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. // Hypertension. 1999. — Vol. 34, № 5. — P. 1047−1052.
- Pawlikovski M., Pisarek H., Kunert-Radek J et al/Somatostatin receptors in GH-secreting pituitary adenomas: relationship with the response to octreotide//90lh Annual Meeting, San Francisco, June 15−18, 2008, Abstract book, P2−714.
- Pereira A.M., Van Thiel S.W., Lindner J.R. et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. // J. Clin. Endocrinol. Metab. -2004. Vol. 89, № 1. — P. 71−75.
- Pergola L., Maison P., Chanson Ph./Efficacy of cabergolin in the treatment of acromegaly: a meta-analysis// 14th Congress of ENEA.- 2010. 22−25 September, Liege, Belgium. Abstract book. — OC-1.1, p.59.
- Pietrobelli D., Akopian M., Olivieri A. et al. Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values. // J. Hum. Hypertens. 2001. — Vol. 15, № 9. — P. 601−605.
- Pizarro CB, Oliveira VC, Coutinho Lb et al/Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody//Braz J Med Biol Res 2004, — Feb., 37(2):235−243.
- Plewe G, Beyer J, Krause U, Neufield M, del Pozo C./ Long-acting and selective supression of GH secretion by somatostatin analog SMS 201−995 in acromegaly// Lancet, 1984, 2, 782−787.
- Rajasoorya C., Holdaway I., Wrightson P. et al. Determinants of clinical outcome and survival in acromegaly. // Clin. Endocrinol. (Oxf). 1994. — Vol. 41, № l.-P. 95−102.
- Reaven G. Insulin resistance, hypertension, and coronary heart disease. // J. Clin. Hypertens. (Greenwich). 2003. — Vol. 5, № 4. — P. 269−74. 34.
- Renehan A.G., Bhaskar P., Painter J.E. et al/The prevalence and characteristics of colorectal neoplasia in acromegaly//Journal of Clinical Endocrinology Metabolism 2000. — N85, 3417−3424.
- Reubi J., Schaer J, laissue J, Waser B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism. 1996, 45 Suppl. 11:39−41.
- Ripa S., Caccamo L., Amati P.C. et al. Severe mitral insufficiency caused by the rupture of the chordae tendinae in acromegaly. Report of a case. // Ital. Heart J. 2001. — Vol. 2, № 9. — Suppl: 1020−1022.
- Robbins R.J. Editorial: Depot somatostatin analogs — a new first line therapy for acromegaly// Journal of Clinical Endocrinology and Metabolism -1997.-82, 1, 15−17.
- Rose D., Clemmons D. Growth hormone receptor antagonist improves insulin resistance in acromegaly // Growth Horm. IGF Res. 2002. — Vol. 12, № 6. — P. 418−424.
- Sacca L., Cittadini A., Fazio S. Growth hormone and the heart. // Endocr. Rev. 1994. — Vol. 15, № 5. -P. 555−573.
- Sandoval C., Gonzales B., Mier F. et al/Correlation between GH receptor Genotype and Clinical/Biocemical Phenotype in Acromegaly// ENDO 08, 90th Annual Meeting, June 15−18, San Francisco, 2008. Abstract book, OR41−1, p. 148.
- Schaison G., Rapport d’Expertise, 1993.
- Scholzen T., Gerdes J./The Ki-67 protein: from the known fnd the unknown//J Cell Physiol 2000. — Mar., 182 (3):311−322.
- Schwartz E., Echemendia E., Schiffer M. and & Panariello V.A./ Mechanism of estrogen action in acromegaly// Journal of Clinical Investigation, 1969, 48, pp. 260−270.
- Scriba P.C., Rapport d’Expertise, 1993.
- Sheppard Michael C. / Primary medical therapy for acromegaly // Clinical Endocrinology 2003. — 58, pp. 387−399.
- Sherlock M., Aragon-Alonso A, Ayuk J., et al/Monitoring acromegaly disease activity with growth hormone and insulin like growth factor I in 501 patients//90th Annual Meeting, San Francisco, June 15−18, 2008, Abstracts book, P2−727.
- Sherlock M., Fernandez-Rodriguez E., Aragon-Alonso A/ et al/ Predictors of response to medical therapy in patients with acromegaly// 90th Annual Meeting, San Francisco, June 15−18, 2008, Abstracts book, P2−733.
- Silha J.V., Krsek M., Hana V. et al. Pertubations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance // Clin. Endocrinol. 2003. — Vol. 58, № 6. — P. 736−742.
- Silverman B., Friedlander J. Is growth hormone good for the heart? // J. Pediatr. 1997. — 131(1 Pt 2): S70−74.
- Simo R., Mesa J., Obiols G. et al. Cardiomegaly and abdominal mass in an acromegalic patient. // Int. J. Card. Imaging. 1987. — Vol. 2, № 3. -P. 161−164.
- Soderberg S., Ahren B., Jansson J. et al. Leptin is associated with increased risk of myocardial infarction. // J. Intern. Med. 1999. — Vol. 246, № 4. — P. 409−418.
- Spinelli L., Petretta M., Verderame G. et al. Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly. // J. Clin. Endocrinol. Metab. 2003. Vol. 88, № 9. — P. 4105−4109.
- Stevenaert A., Harris A.G., Kovacs K. et al /Presurgical octreotide treatment in acromegaly // Metabolism 1992. — V41, (Suppl 2), pp.51−58.
- Stewart P.M., Kane K.F., Stewart S.E. et al/ Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly//Journal of Clinical Endocrinol Metab. 1995. — 80, pp. 3267−3272.
- Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998. — 83(10):3419−3426.
- Takizawa H., Ura N., Saitoh S. et al. Gender difference in the relationships among hyperleptinemia, hyperinsulinemia, and hypertension. // Clin. Exp. Hypertens. 2001. — Vol. 23, № 4. — P. 357−368.
- Tan K., Shiu S., Janus E., Lam K. LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-1 //Atherosclerosis. 1997. — Vol. 129, № 1. P. 59−65.
- Terzolo M., Avonto L., Matrella C. et al. Doppler echo-ardiographic patterns in patients with acromegaly. // J. Endocrinol. Invest. 1995. — Vol.18, № 8. — P. 613−620.
- Terzolo M., Matrella C., Boccuzzi A. et al. Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. // J. Endocrinol. Invest. 1999. — Vol. 22, № 1. — P. 48−54.
- Thapar K., K.T., Stefaneanu L. et al /Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial // Mayo Clin. Proc. 1997. -V72, pp. 893−900.
- Thorner Michael O. Controversy: radiotherapy for acromegaly // Clinical Endocrinology 2003. — V. 58, pp. 136−137.
- Tomlinson J .W., Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM/ Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group// Lancet 2001. — 357, pp. 425−431.
- Tsuchiya H., Onishi T., Mogami H., lida M./Lipid metabolism in acromegalic patients before and after selective pituitary adenomectomy // Endocrinol. Jpn. -1990. Vol.37, № 6. — P. 797−807.
- Tugan D., Demirtas E., Ozdamar N. et al/Clinico-pathological features of pituitary adenomas. Correlation between Ki-67 proliferation index and recurrence of invasionZ/Journal of Neurological Sciences (Turkish). -1999. -V16.-Issue 2: April-June, #17.
- Thorner MO, Chait A, Aitken M. et al/Bromocriptine treatment of acromegaly//British Medical Journal 1975. — i, pp. 299−303.
- Turner H.E., A. Vadivale, J. Keenan and J.A.H. Wass et al/A comparison of lanreotide and octreotide LAR for treatment of acromegaly//Clinical Endocrinoly 1999. — 51, pp. 275−280.
- Turner H.E., Harris A.L., Melmed S. and Wass J.A.H./Angiogenesis in Endocrine tumors//Endocr.Rev" — 2003. -October 1, 24(5):600−632.
- Turner H.E., Nagy Z., Gatter K.C. et al/ Angiogenesis in pituitary adenomas relationship to endocrine function, treatment and outcome//J. Endocrinol. — 2000. -May -165(2):475−481.
- Twardowski R., Mandecki T., Mizia-Stec K. et al. Left and right ventricular function in acromegalic patients. // Pol. Arch. Med. Wewn. 2001. — Vol. 106, № 2. — P. 669−674.
- Vale W, Brazeau P, Grant G, et al/ Premieres observations sur le mode d’action de la somatostatine un facteur hypothalamique qui inhibe la secretion de l’hormone do auissnncc// C R Acad Sci (Paris), 1972, 275, pp. 2913−2915.
- Van Herpen G., Ritsema van Eck H.J., Kors J.A. The evidence against QT-dispersion. // Inernat. J. of Bioelectromagnetism. 2003. — Vol. 5, № 1. — P. 231 233.
- Verhelst J.A., Pedroncelli A.M., Abs R, et al/ Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients//European Journal of Endocrinology 2000. — 143, 577−584.
- Vianna C.B., Vieira M.L., Mady C. et al. Treatment of acromegaly improves myocardial abnormalities. // Am. Heart J. 2002. — Vol. 143, № 5. — P. 873−876.
- Volterrani M., Giustina A., Lorusso R., Giordano A. Does growth hormone play a role in chronic heart failure? // Heart Fail Monit. 2002. — Vol. 3, № 2. — P.60−64.
- Volterrani M., Giustina A., Manelli F. et al. Role of growth hormone in chronic heart failure: therapeutic implications. // Ital. Heart J. 2000. — Vol. 1, № 11. — P.732−738.
- Wass J.A.H. Radiotherapy in acromegaly: a protagonists viewpoint // Clinical Endocrinology 2003. — V 58, pp. 128−131.
- Yamamoto T., Nakamura H., Ogawa T. et al. Acromegalics with multiple cardiovascular complications cardiomyopathy, chordae rupture of mitral valve, myocardial infarction and sick sinus syndrome. // Intern. Med. — 2003. — Vol. 42, № 8. — P. 700−703.
- Yasuda T., Kawasuji M., Sakakibara N. et al. A case of left ventricular aneurysm associated with acromegaly. // Kyobu Geka. 1993. — Vol. 46, № 7. -P. 605−609.
- Zhao D., Tomono Y., Nose /Expression of P27kipl and Ki-67 in pituitary adenomas: an investigation of marker of adenoma invasiveness.//Acta Neurohir.(Wein) 1999- 141 (2):187−192.